This announcement contains inside information 16 August 2016 07:00 ASTRAZENECA COMPLETES GLOBAL LICENCING AGREEMENT WITH LEO PHARMA FOR TRALOKINUMAB AstraZeneca today announced that it has completed the licensing agreement (https://www.astrazeneca.com/media-centre/press -releases/2016/astrazeneca-enters-licensing-agreements-with-leo-pharma-in-skin -diseases-01072016.html) with LEO Pharma A/S (LEO Pharma), a specialist in dermatology care, for the global licence to tralokinumab in skin diseases. Tralokinumab is an IL-13 monoclonal antibody that has completed a Phase IIb trial for the treatment of patients with atopic dermatitis, an inflammatory skin disease resulting in itchy, red, swollen and cracked skin. Upon completion of the agreement, LEO Pharma made a payment to AstraZeneca of $115 million for the exclusive, global rights to tralokinumab in atopic dermatitis and any future additional dermatology indications. As AstraZeneca will retain a significant ongoing interest in tralokinumab, the upfront payment, along with all future commercial milestone and royalty payments, will be reported as Externalisation Revenue in the Company's financial statements. About AstraZeneca AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Respiratory and Autoimmunity, Cardiovascular and Metabolic Diseases, and Oncology. The Company is also active in inflammation, infection and neuroscience through numerous collaborations. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com CONTACTS Media Enquiries Neil UK/Global    +44 203 749 5637 Burrows Vanessa UK/Global    +44 203 749 5736 Rhodes Karen UK/Global    +44 203 749 5634 Birmingham Rob UK/Global    +44 203 749 5821 Skelding Jacob Lund    Sweden    +46 8 553 260 20 Michele US    +1 302 885 2677 Meixell Investor Relations UK Thomas Kudsk +44 203 749 5712 Larsen Craig Marks  Finance, Fixed Income, M&A +44 7881 615 764 Nick Stone  Respiratory & Autoimmunity +44 203 749 5716 Henry Oncology  +44 203 749 5797 Wheeler Christer Infection & Neuroscience +44 203 749 5711 Gruvris US Lindsey Cardiovascular & Metabolic   Diseases +1 240 543 7970 Trickett Mitchell  Oncology +1 240 477 3771 Chan Toll free +1 866 381 7277 Adrian Kemp Company Secretary AstraZeneca PLC -ENDS-

Ads